Jonathan Sadeh

968 total citations
20 papers, 705 citations indexed

About

Jonathan Sadeh is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Jonathan Sadeh has authored 20 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Rheumatology. Recurrent topics in Jonathan Sadeh's work include Asthma and respiratory diseases (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Respiratory and Cough-Related Research (5 papers). Jonathan Sadeh is often cited by papers focused on Asthma and respiratory diseases (10 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers) and Respiratory and Cough-Related Research (5 papers). Jonathan Sadeh collaborates with scholars based in United States, France and United Kingdom. Jonathan Sadeh's co-authors include Paul Stryszak, Paul M. O’Byrne, Mina Gaga, Parameswaran Nair, Pascal Chanez, F.E. Hargreave, Εleftherios Ζervas, Khuder Alagha, Andrea Ludwig-Sengpiel and Paresh Soni and has published in prestigious journals such as CHEST Journal, Annals of the Rheumatic Diseases and European Respiratory Journal.

In The Last Decade

Jonathan Sadeh

20 papers receiving 691 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jonathan Sadeh	375	277	270	138	90	20	705
G Prosperini	395 1.1×	363 1.3×	66 0.2×	49 0.4×	102 1.1×	31	660
Venkat Subramaniam	173 0.5×	118 0.4×	114 0.4×	76 0.6×	131 1.5×	12	426
Anna Stasiak‐Barmuta	110 0.3×	87 0.3×	270 1.0×	76 0.6×	114 1.3×	87	645
B. Schlüter	120 0.3×	76 0.3×	116 0.4×	22 0.2×	118 1.3×	46	471
Tilo Brunnée	182 0.5×	105 0.4×	118 0.4×	22 0.2×	100 1.1×	21	583
Qijun Zheng	79 0.2×	124 0.4×	131 0.5×	61 0.4×	266 3.0×	24	710
Brittany Salter	670 1.8×	280 1.0×	502 1.9×	26 0.2×	81 0.9×	38	983
Marie Fischer	86 0.2×	37 0.1×	373 1.4×	145 1.1×	81 0.9×	33	676
Hirokazu Kondo	104 0.3×	150 0.5×	27 0.1×	49 0.4×	184 2.0×	77	820
Malin E. Winerdal	46 0.1×	114 0.4×	324 1.2×	167 1.2×	147 1.6×	15	660

Countries citing papers authored by Jonathan Sadeh

Since Specialization

Citations

This map shows the geographic impact of Jonathan Sadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Sadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Sadeh more than expected).

Fields of papers citing papers by Jonathan Sadeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Sadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Sadeh. The network helps show where Jonathan Sadeh may publish in the future.

Co-authorship network of co-authors of Jonathan Sadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Sadeh. A scholar is included among the top collaborators of Jonathan Sadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Sadeh. Jonathan Sadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gabay, Cem, Gerd R Burmester, Vibeke Strand, et al.. (2020). Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Research & Therapy. 22(1). 70–70. 32 indexed citations

Boyapati, Anita, Sergio Schwartzman, Jérôme Msihid, et al.. (2020). Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis & Rheumatology. 72(9). 1456–1466. 36 indexed citations

Boyapati, Anita, Jérôme Msihid, Sergio Schwartzman, et al.. (2019). 069 High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. Lara D. Veeken. 58(Supplement_3). 5 indexed citations

Strand, Vibeke, Owen Hagino, Susan Boklage, et al.. (2018). SAT0207 Depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment. Annals of the Rheumatic Diseases. 77. 964–964. 1 indexed citations

Strand, Vibeke, Owen Hagino, Susan Boklage, et al.. (2018). THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab. Annals of the Rheumatic Diseases. 77. 332–332. 2 indexed citations

Aranda, Jacob V., Charles L. Cai, Jonathan Sadeh, et al.. (2016). Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy. Pediatric Research. 80(4). 554–565. 36 indexed citations

Salter, Brittany, Desmond M. Murphy, Richard M. Watson, et al.. (2016). The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects. Pulmonary Pharmacology & Therapeutics. 41. 34–39. 39 indexed citations

Nair, Parameswaran, Mina Gaga, Εleftherios Ζervas, et al.. (2012). Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial. Clinical & Experimental Allergy. 42(7). 1097–1103. 271 indexed citations

McLeod, Robbie L., Deen Tulshian, & Jonathan Sadeh. (2011). Where Are the New Cough Treatments: A Debriefing of Recent Clinical Proof-of-Concept Trials with the NOP Agonist SCH 486757. Pharmacology. 88(1-2). 50–54. 10 indexed citations

10.

Kerwin, Edward, et al.. (2011). Quality of Life Following 26 Weeks of Mometasone Furoate/Formoterol Therapy: Results From Two Phase Three Trials in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease. CHEST Journal. 140(4). 558A–558A. 2 indexed citations

11.

Doherty, Dennis E., et al.. (2011). The Long-term Safety Characteristics of Mometasone Furoate/Formoterol for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Pooled Findings From Two 1-Year Multicenter Clinical Trials. CHEST Journal. 140(4). 548A–548A. 2 indexed citations

12.

Doherty, Dennis E., et al.. (2011). Efficacy and Safety of Mometasone Furoate/Formoterol in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease: Results From Two Phase Three 26-Week Trials. CHEST Journal. 140(4). 535A–535A. 2 indexed citations

13.

Tashkin, Donald P., et al.. (2011). The Effect of Mometasone Furoate/Formoterol Combination Therapy on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: Results From Two Phase Three Trials in Subjects With Moderate to Very Severe COPD. CHEST Journal. 140(4). 549A–549A. 2 indexed citations

14.

Kazani, Shamsah, et al.. (2010). Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. Respiratory Medicine. 105(5). 667–673. 9 indexed citations

15.

Murphy, Desmond M., Richard M. Watson, Karen Howie, et al.. (2010). Treatment With The CXCR2 Antagonist SCH527123 Reduced Neutrophil Levels In Blood And Airways But Not Bone Marrow In Mild Asthmatic Subjects. A4237–A4237. 7 indexed citations

16.

Gaga, Mina, Parameswaran Nair, Frederick E. Hargreave, Jonathan Sadeh, & Pascal Chanez. (2010). SCH527123, a Novel Treatment Option For Severe Neutrophilic Asthma. A6763–A6763. 6 indexed citations

17.

Holz, Olaf, Sauzanne Khalilieh, Andrea Ludwig-Sengpiel, et al.. (2009). SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. European Respiratory Journal. 35(3). 564–570. 150 indexed citations

18.

Woodcock, Ashley, Robbie L. McLeod, Jonathan Sadeh, & John A. Smith. (2009). The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough. Lung. 188(S1). 47–52. 33 indexed citations

19.

O’Regan, Anthony, Jonathan Sadeh, & Jeffrey S. Berman. (2002). The effect of unfractionated heparin on circulating lymphocyte counts and subsets in humans. Thrombosis Research. 106(1). 31–33. 2 indexed citations

20.

Barthlen, Gabriele, et al.. (2000). Comparison of three oral appliances for treatment of severe obstructive sleep apnea syndrome. Sleep Medicine. 1(4). 299–305. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact